Pink SheetThe EU marketing authorization applications (MAAs) for three medicines were voluntarily withdrawn by their applicants this month before the European Medicines Agency could issue an opinion on whether
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Lilly To Discover, Develop Oligonucleo
In VivoPharmaceutical companies have a variety of strategic options available to them to restock pipelines and ensure continued innovation. In terms of external innovation, in-licensing assets from other com
Pink SheetThe European Medicines Agency has begun reviewing for potential pan-EU marketing approval 10 new products, including depemokimab, GSK’s IL-5 inhibitor that could become the first ultra-long-acting dru